TrialLeukemia2020

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

C Ola Landgren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.